Metabolic and Hemodynamic Effects of the Inhibitors of Type 2 Sodium Glucose Co-transporters (ISGLT2) in Diabetic Patients With Heart Failure (GLUCOSUR-IC)

Germans Trias i Pujol Hospital

Status: Completed

Conditions: Heart Failure

Treatments: Drug: iSGTL2

Study type: Observational

Funder types: Other

Identifiers

NCT03741972

ICO-2018-03-PA-Glucosur

Details and patient eligibility

About

Inhibitors of the type 2 sodium-glucose co-transporter (iSGLT2) may improve the metabolic and hemodynamic profile in patients with DM2 and heart failure.

Enrollment: 100 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Type 2 Diabetes
• HbA1c> 6.5%
• Estimated GF> 45 ml / min
• BMI: ≥25 Kg / m2
• Stable pharmacological treatment of Heart Failure in the last 3 months

Exclusion criteria

• Diabetes type 1 or type LADA (presence of antibodies against GAD and/or IA-2 positive)
• DM2 with C-peptide <1 ng / mL
• GEF <45 ml / min
• Recurrent urinary tract infections

Trial design

100 participants in 1 patient group

Treatment

Description:

Patients with diabetes and heart failure that are treated with iSGLT2

Treatment:

Drug: iSGTL2